Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 114

Sort by

Sort Order Select

Journal Articles

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)

Thomas Schroeder, Matthias Stelljes, Maximilian Christopeit, Eva Schmidt, Christoph Scheid, Jan-Henrik Mikesch, Christina Rautenberg, Paul Jäger, Nadja Drusenheimer, Udo Holtick, Stefan Klein, Rudolf Trenschel, Rainer Haas, Ulrich Germing, Nicolaus Kröger, Guido Kobbe

Blood (2021) 138 (Supplement 1): 411.

https://doi.org/10.1182/blood-2021-153282

Published: 2021

Journal Articles

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Christina Rautenberg, Friedrich Stölzel, Christoph Röllig, Matthias Stelljes, Verena I Gaidzik, Michael Lauseker, Oliver Kriege, Mareike Verbeek, Julia M. Unglaub, Felicitas Thol, Stefan W. Krause, Mathias Haenel, Charlotte Neuerburg, Vladan Vucinic, Christian Jehn, Julia Severmann, Maxi Wass, Lars Fransecky, Jens Chemnitz, Udo Holtick, Kerstin Schäfer-Eckart, Josephine Schröder, Sabrina Kraus, William Hermann Krüger, Ulrich Kaiser, Sebastian Scholl, Lea Henning, Guido Kobbe, Rainer Haas, Nael Alakel, Maximilian Alexander Röhnert, Katja Sockel, Maher Hanoun, Uwe Platzbecker, Tobias A. W. Holderried, Anke Morgner, Michael Heuser, Tim Sauer, Katharina S. Goetze, Eva Maria Wagner, Konstanze Döhner, Hartmut Döhner, Christoph Schliemann, Johannes Schetelig, Martin Bornhäuser, Ulrich Germing, Thomas Schroeder, Moritz Moritz Middeke

Blood (2021) 138 (Supplement 1): 33.

https://doi.org/10.1182/blood-2021-153440

Published: 2021

Journal Articles

Impaired Formation of Neutrophil Extracellular Traps (NETs) in Patients with Myelodysplastic Syndrome (MDS)

Carolin Brings, Ron-Patrick Cadeddu, PhD, Julia Fröbel, PhD, Hubert Schelzig, MD, Rainer Haas, MD, Norbert Gattermann, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-138409

Published: 2020

Journal Articles

Therapy-Related Myeloid Neoplasms Following Treatment for Multiple Myeloma : A Single-Center Analysis

Amelie Boquoi, MD, Soraya Magdalena Banahan, MD, Judith Strapatsas, MD, David Lopez y Niedenhoff, MD, Guido Kobbe, MD, Norbert Gattermann, MD, Ulrich Germing, MD, Rainer Haas, MD, Thomas Schroeder, MD, Roland Fenk, MD

Blood (2019) 134 (Supplement_1): 4261.

https://doi.org/10.1182/blood-2019-122598

Published: 2019

Journal Articles

Combined Retro- and Prospective Analysis of Adherence to Guidelines and Patient-Tailored Therapeutic Recommendations in Patients with Myelodysplastic Syndromes (MDS) at a Tertiary Care Centre

Annika Kasprzak, Kathrin Nachtkamp, MD, Mustafa Kondakci, MD, Thomas Schroeder, MD, Guido Kobbe, MD, Andrea Kündgen, MD, Jennifer Kaivers, MD, Christina Rautenberg, MD, Rainer Haas, MD, Norbert Gattermann, MD, Nicolas Bonadies, MD, Ulrich Germing, MD

Blood (2019) 134 (Supplement_1): 4250.

https://doi.org/10.1182/blood-2019-124512

Published: 2019

Journal Articles

Impact of Somatic Mutations and Pretransplant Strategies on the Outcome of Patients Allografted for MDS or Secondary AML

Christina Rautenberg, MD, Stefanie Stepanow, Michael Lauseker, Ulrich Germing, MD, Paul Jäger, Stefanie Geyh, Esther Schuler, Karl Köhrer, Norbert Gattermann, MD, Rainer Haas, MD, Guido Kobbe, MD, Thomas Schroeder, MD

Blood (2019) 134 (Supplement_1): 4612.

https://doi.org/10.1182/blood-2019-126565

Published: 2019

Journal Articles

Prognostic Value of Circulating Bcl-2/Igh Levels before and after Treatment in 415 Patients with Advanced Follicular Lymphoma Receiving First-Line Immuno-Chemotherapy in 2 Prospective StiL Trials - the Effect of Rituximab Maintenance

Guido Kobbe, Sabrina Pechtel, Fabian Zohren, MD PhD, Jürgen Barth, Alexander Christoph Burchardt, MD, Christian Buske, MD, Ariane Dienst, MD, Ulrich Germing, MD, Richard Greil, MD, Bernd Hertenstein, MD, Frank Kauff, Michael Koenigsmann, MD, Christian Lerchenmüller, MD, Thomas Michael Schroeder, MD PhD, Rainer Haas, MD, Mathias J Rummel, MD PhD

Blood (2018) 132 (Supplement 1): 4149.

https://doi.org/10.1182/blood-2018-99-118750

Published: 2018

Journal Articles

WT1 mRNA Expression in the Peripheral Blood of Patients with MDS Yields Additional Prognostic Information within the IPSS-R Risk Categories "Very Low", "Low" and "Intermediate"

Christina Rautenberg, MD, Sabrina Pechtel, Norbert Gattermann, MD, Rainer Haas, MD, Ulrich Germing, MD, Guido Kobbe, Thomas Michael Schroeder, MD PhD

Blood (2018) 132 (Supplement 1): 1827.

https://doi.org/10.1182/blood-2018-99-113524

Published: 2018

Journal Articles

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691)

Thomas Michael Schroeder, MD PhD, Christina Rautenberg, MD, Max Christopeit, Matthias Stelljes, MD, Eva Schmidt, Christoph Groth, MD, Christoph Scheid, MD, Udo Holtick, MD PhD, Stefan A Klein, MD, Dietrich W. Beelen, Kathrin Nachtkamp, MD, Rainer Haas, MD, Ulrich Germing, MD, Nicolaus Kröger, MD, Guido Kobbe

Blood (2018) 132 (Supplement 1): 703.

https://doi.org/10.1182/blood-2018-99-113776

Published: 2018

Journal Articles

Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Andrea Kuendgen, MD, Meritxell Nomdedeu, Heinz Tuechler, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, Alan F. List, MD, Mario Cazzola, Amy E. DeZern, MD, Gail J. Roboz, MD, David P. Steensma, MD, Arjan A. Van de Loosdrecht, MD PhD, Hartmut Döhner, MD, Xavier Calvo, MD, Sabine Blum, Arturo Pereira, MD PhD, Peter Valent, Dolors Costa, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, Carme Pedro, MD, Michael Lübbert, Itziar Oiartzabal, Javier Grau, Maria Díez-Campelo, María Teresa Cedena, Sigrid Machherndl-Spandl, MD, Maria López-Pavía, Claudia D. Baldus, MD, Montserra Martinez-de-Sola, Reinhard Stauder, MD MSc, Brayan Merchan, Christina Ganster, Thomas Schroeder, Barbara Hildebrandt, Jordi Esteve, MD PhD, Benet Nomdedeu, Francesc Cobo, Francesc Sole, PhD, Rainer Haas, MD, Ulrich Germing, MD, Peter L Greenberg, MD, Detlef Haase, MD PhD, Guillermo Sanz

Blood (2018) 132 (Supplement 1): 3103.

https://doi.org/10.1182/blood-2018-99-118215

Published: 2018

Journal Articles

Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: Results of the Lenamain Trial

Amelie Boquoi, MD, Aristoteles Giagounidis, Hartmut Goldschmidt, MD, Michael Heinsch, MD, Mathias J Rummel, MD PhD, Nicolaus Kroeger, David Lopez y Niedenhoff, MD, C. Matthias Wilk, MD, Ingrida Savickaite, MD, Elias K Mai, MD, Carlo Aul, MD, Judith Strapatsas, MD, Ariane Dienst, MD, Mustafa Kondakci, MD, Rainer Haas, MD, Guido Kobbe, Roland Fenk, MD PhD

Blood (2018) 132 (Supplement 1): 2003.

https://doi.org/10.1182/blood-2018-99-110977

Published: 2018

Journal Articles

Quantitative Next-Generation Sequencing (NGS) Based Monitoring of Minimal Residual Disease (MRD) Predicts Imminent Relapse in Patients with Myeloid Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Christina Rautenberg, MD, Beate Betz, Dagmar Wieczorek, Barbara Hildebrandt, Kathrin Nachtkamp, MD, Esther Schuler, Norbert Gattermann, MD, Guido Kobbe, MD, Rainer Haas, MD, Thomas Schroeder, MD

Blood (2017) 130 (Supplement 1): 2005.

https://doi.org/10.1182/blood.V130.Suppl_1.2005.2005

Published: 2017

Journal Articles

Treatment of Relapse of MDS, AML and CMML after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Results from the First Interim Analysis of the Azalena-Trial (NCT02472691)

Thomas Schroeder, MD, Christina Rautenberg, MD, Max Christopeit, Matthias Stelljes, MD, Eva Schmidt, Stefan Klein, MD, Christof Scheid, MD, Dietrich W Beelen, MD PhD, Kathrin Nachtkamp, MD, Rainer Haas, MD, Ulrich Germing, MD, Nicolaus Kröger, Guido Kobbe, MD

Blood (2017) 130 (Supplement 1): 4521.

https://doi.org/10.1182/blood.V130.Suppl_1.4521.4521

Published: 2017

Journal Articles

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

Fatemeh Majidi, MD, Judith Neukirchen, MD, Simon Brille, Iris Fey, BSc., Frank Neumann, MDPhD, Allison Berger, PhD, Ron-Patrick Cadeddu, PhD, Martina Rudelius, MD, Ulrich Germing, MD, Rainer Haas, MD, Norbert Gattermann, MD

Blood (2017) 130 (Supplement 1): 5298.

https://doi.org/10.1182/blood.V130.Suppl_1.5298.5298

Published: 2017

Journal Articles

Multicenter Case Series of Primary Adrenal Lymphoma (PAL)

Blood (2017) 130 (Supplement 1): 1562.

https://doi.org/10.1182/blood.V130.Suppl_1.1562.1562

Published: 2017

Journal Articles

Coronin 1A, a novel player in integrin biology, controls neutrophil trafficking in innate immunity

Robert Pick, Daniela Begandt, Thomas J. Stocker, Melanie Salvermoser, Sarah Thome, Ralph T. Böttcher, Eloi Montanez, Ute Harrison, Ignasi Forné, Alexander G. Khandoga, Raffaele Coletti, Ludwig T. Weckbach, Doris Brechtefeld, Rainer Haas, Axel Imhof, Steffen Massberg, Markus Sperandio, Barbara Walzog

Blood (2017) 130 (7): 847–858.

https://doi.org/10.1182/blood-2016-11-749622

Published: 2017

Includes: Multimedia, Supplemental data

Journal Articles

Concordant Underexpression of Fanconi Anemia/BRCA1 Pathway Proteins in a Major Proportion of Myelodysplastic Syndromes

Fatemeh Majidi, MD, Judith Neukirchen, MD, Ulrich Germing, M. D., Ron-Patrick Cadeddu, Stefan Braunstein, MD, Rainer Haas, MD, Norbert Gattermann, MD

Blood (2016) 128 (22): 4311.

https://doi.org/10.1182/blood.V128.22.4311.4311

Published: 2016

Journal Articles

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Andrea Kuendgen, MD, Heinz Tuechler, Meritxell Nomdedeu, MD, Detlef Haase, MD, Guillermo Garcia-Manero, MD, Rami S. Komrokji, MD, Francesc Sole, PhD, Mikkael A. Sekeres, MD MS, Matteo Giovanni Della Porta, MD, Alan F List, MD, Mario Cazzola, MD, Amy E. DeZern, MD MHS, Gail J. Roboz, David P. Steensma, MD, Arjan A. van de Loosdrecht, MD PhD, Richard F. Schlenk, MD, Xavier Calvo, MD, Sabine Blum, MD, Arturo Pereira, Arturo Pereira, Peter Valent, MD, Dolors Costa, Dolors Costa, Aristoteles Giagounidis, Aristoteles Giagounidis, Luis Benlloch, Uwe Platzbecker, MD, Carmen Pedro, MD, Michael Lübbert, MD, María Teresa Cedena, MD, Julie Schanz, MD, Sigrid Machherndl-Spandl, MD, Maria Lopez-Pavia, MD, María Díez-Campelo, MD, Claudia D. Baldus, MD, Montserrat Martínez de Sola, Reinhard Stauder, MD, Brayan Merchan, MD, Claudia Mende, Maria Teresa Voso, MD, Maria Teresa Voso, MD, Itziar Oiartzabal, Itziar Oiartzabal, Christina Ganster, PhD, Francesc Cobo, Thomas Schroeder, MD, Jordi Esteve, Rainer Haas, MD, Benet Nomdedeu, Peter Greenberg, MD, Ulrich Germing, Guillermo Sanz, MD

Blood (2016) 128 (22): 112.

https://doi.org/10.1182/blood.V128.22.112.112

Published: 2016

Journal Articles

Decitabine As Salvage Therapy for Relapse of AML and MDS after Allogeneic Stem Cell Transplantation - a Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group

Thomas Schroeder, MD, Christina Rautenberg, MD, William Hermann Krüger, MD PhD, Uwe Platzbecker, MD, Gesine Bug, MD, Steinmann Juliane, Stefan A. Klein, MD, Olaf Hopfer, Kathrin Nachtkamp, MD, Ariane Dienst, MD, Mustafa Kondakci, MD, Pia Verena Schmidt, MD, Claudia Heyn, MD, Rainer Haas, MD, Ulrich Germing, Martin Bornhäuser, MD, Guido Kobbe, MD

Blood (2016) 128 (22): 3446.

https://doi.org/10.1182/blood.V128.22.3446.3446

Published: 2016

Journal Articles

Comparison Between Wilms' Tumor 1 (WT1) Expression Using a Standardized European Leukemia Net (ELN)-Certified Assay and Other Methods for Detection of Minimal Residual Disease (MRD) in MDS and AML Patients after Allogeneic Blood Stem Cell Transplantation

Christina Rautenberg, MD, Sabrina Pechtel, Barbara Hildebrandt, Beate Betz, Ariane Dienst, MD, Kathrin Nachtkamp, MD, Stefanie Geyh, Pia Verena Schmidt, MD, Claudia Heyn, MD, Mustafa Kondakci, MD, Norbert Gattermann, MD, Rainer Haas, MD, Ulrich Germing, Guido Kobbe, MD, Thomas Schroeder, MD

Blood (2016) 128 (22): 3447.

https://doi.org/10.1182/blood.V128.22.3447.3447

Published: 2016

NARROW

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Final Results of the Prospective Azalena-Trial (NCT02472691)

Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Impaired Formation of Neutrophil Extracellular Traps (NETs) in Patients with Myelodysplastic Syndrome (MDS)

Therapy-Related Myeloid Neoplasms Following Treatment for Multiple Myeloma : A Single-Center Analysis

Combined Retro- and Prospective Analysis of Adherence to Guidelines and Patient-Tailored Therapeutic Recommendations in Patients with Myelodysplastic Syndromes (MDS) at a Tertiary Care Centre

Impact of Somatic Mutations and Pretransplant Strategies on the Outcome of Patients Allografted for MDS or Secondary AML

Prognostic Value of Circulating Bcl-2/Igh Levels before and after Treatment in 415 Patients with Advanced Follicular Lymphoma Receiving First-Line Immuno-Chemotherapy in 2 Prospective StiL Trials - the Effect of Rituximab Maintenance

WT1 mRNA Expression in the Peripheral Blood of Patients with MDS Yields Additional Prognostic Information within the IPSS-R Risk Categories "Very Low", "Low" and "Intermediate"

Treatment of MDS, AML and CMML Relapse after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions Results from the Second Interim Analysis of the Prospective Azalena-Trial (NCT02472691)

Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS

Similar Quality of Life with 5mg Versus 25mg Lenalidomide Maintenance after First-Line High-Dose Therapy and Autologous Blood Stem Cell Transplantation for Multiple Myeloma: Results of the Lenamain Trial

Quantitative Next-Generation Sequencing (NGS) Based Monitoring of Minimal Residual Disease (MRD) Predicts Imminent Relapse in Patients with Myeloid Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation

Treatment of Relapse of MDS, AML and CMML after Allogeneic Blood Stem Cell Transplantation with Azacitidine, Lenalidomide and Donor Lymphocyte Infusions - Results from the First Interim Analysis of the Azalena-Trial (NCT02472691)

Altered Expression of Neddylation Pathway Proteins in Myelodysplastic Syndromes

Multicenter Case Series of Primary Adrenal Lymphoma (PAL)

Coronin 1A, a novel player in integrin biology, controls neutrophil trafficking in innate immunity

Concordant Underexpression of Fanconi Anemia/BRCA1 Pathway Proteins in a Major Proportion of Myelodysplastic Syndromes

Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS)

Decitabine As Salvage Therapy for Relapse of AML and MDS after Allogeneic Stem Cell Transplantation - a Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group

Comparison Between Wilms' Tumor 1 (WT1) Expression Using a Standardized European Leukemia Net (ELN)-Certified Assay and Other Methods for Detection of Minimal Residual Disease (MRD) in MDS and AML Patients after Allogeneic Blood Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only